On February 14, 2020, the entity that manages the Swiss DRG system, SwissDRG, clarified the add-on reimbursement ZE-2020-129 for Elbasvir and Grazoprevir.
This was done because, at the end of last year, the drug Elbasvir and Grazoprevir (oral) was included in the list of drugs, and therefore the provisions of articles 71a and 71b of the Ordinance on health insurance (OAMal/KVV) are not applicable to this additional reimbursement.
The add-on reimbursement can only be billed for the oral use of preparations, with the combination of 100 mg Grazoprevir / 50 mg Elbasvir (e.g., Zepatier®). The add-on reimbursement amount ranges from CHF 1,079.08 to 7,913.24, depending on the unit dose.
More details can be seen in Italian (switch to German or French in the top-right corner) here. Subscribe
to our newsletter delivered every second week not to miss important reimbursement information.